Allogene Therapeutics Statistics
Total Valuation
ALLO has a market cap or net worth of $753.31 million. The enterprise value is $594.95 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALLO has 343.98 million shares outstanding. The number of shares has increased by 13.25% in one year.
| Current Share Class | 343.98M |
| Shares Outstanding | 343.98M |
| Shares Change (YoY) | +13.25% |
| Shares Change (QoQ) | +1.80% |
| Owned by Insiders (%) | 4.57% |
| Owned by Institutions (%) | 36.73% |
| Float | 268.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 74,697.17 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 2.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.93, with a Debt / Equity ratio of 0.28.
| Current Ratio | 7.93 |
| Quick Ratio | 7.74 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -192.50 |
Financial Efficiency
Return on equity (ROE) is -53.42% and return on invested capital (ROIC) is -29.11%.
| Return on Equity (ROE) | -53.42% |
| Return on Assets (ROA) | -26.82% |
| Return on Invested Capital (ROIC) | -29.11% |
| Return on Capital Employed (ROCE) | -53.97% |
| Weighted Average Cost of Capital (WACC) | 6.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.26M |
| Employee Count | 152 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.97% in the last 52 weeks. The beta is 0.54, so ALLO's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +40.97% |
| 50-Day Moving Average | 2.41 |
| 200-Day Moving Average | 1.60 |
| Relative Strength Index (RSI) | 43.93 |
| Average Volume (20 Days) | 16,897,518 |
Short Selling Information
The latest short interest is 36.38 million, so 10.58% of the outstanding shares have been sold short.
| Short Interest | 36.38M |
| Short Previous Month | 32.06M |
| Short % of Shares Out | 10.58% |
| Short % of Float | 13.54% |
| Short Ratio (days to cover) | 5.87 |
Income Statement
| Revenue | n/a |
| Gross Profit | -150.15M |
| Operating Income | -206.93M |
| Pretax Income | -190.89M |
| Net Income | -190.89M |
| EBITDA | -194.57M |
| EBIT | -206.93M |
| Earnings Per Share (EPS) | -$0.87 |
Full Income StatementBalance Sheet
The company has $250.21 million in cash and $83.25 million in debt, giving a net cash position of $166.96 million or $0.49 per share.
| Cash & Cash Equivalents | 250.21M |
| Total Debt | 83.25M |
| Net Cash | 166.96M |
| Net Cash Per Share | $0.49 |
| Equity (Book Value) | 292.54M |
| Book Value Per Share | 1.28 |
| Working Capital | 225.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$149.25 million and capital expenditures -$386,000, giving a free cash flow of -$149.63 million.
| Operating Cash Flow | -149.25M |
| Capital Expenditures | -386,000 |
| Depreciation & Amortization | 12.36M |
| Net Borrowing | n/a |
| Free Cash Flow | -149.63M |
| FCF Per Share | -$0.44 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |